{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:45:05Z","timestamp":1784609105532,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bcp.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:36:45Z","timestamp":1554374205000},"page":"336-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Keep recycling going: New approaches to reduce LDL-C"],"prefix":"10.1016","volume":"164","author":[{"given":"Andres J.P.","family":"Klein-Szanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-3169","authenticated-orcid":false,"given":"Daniel E.","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7635","key":"10.1016\/j.bcp.2019.04.003_b0005","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(69)90930-1","article-title":"Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states","volume":"2","author":"Slack","year":"1969","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2015.08.038","article-title":"Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"243","author":"Barkas","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"45","key":"10.1016\/j.bcp.2019.04.003_b0020","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Atherosclerosis Society Consensus, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"32","key":"10.1016\/j.bcp.2019.04.003_b0025","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.003_b0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.003_b0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10038-003-0114-3","article-title":"Genetic variants in PCSK9 affect the cholesterol level in Japanese","volume":"49","author":"Shioji","year":"2004","journal-title":"J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.003_b0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.04.003_b0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-8993(99)01909-5","article-title":"Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides","volume":"848","author":"Seidah","year":"1999","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mc.20134","article-title":"Proprotein convertases: \u201cmaster switches\u201d in the regulation of tumor growth and progression","volume":"44","author":"Bassi","year":"2005","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol. Rev."},{"issue":"47","key":"10.1016\/j.bcp.2019.04.003_b0085","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4746","key":"10.1016\/j.bcp.2019.04.003_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2019.04.003_b0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"18","key":"10.1016\/j.bcp.2019.04.003_b0100","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"48","key":"10.1016\/j.bcp.2019.04.003_b0105","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.003_b0110","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"Suppl","key":"10.1016\/j.bcp.2019.04.003_b0115","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","article-title":"New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications","volume":"27","author":"Seidah","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0125","first-page":"225","article-title":"Statin intolerance: some practical hints","volume":"36","author":"Banach","year":"2018","journal-title":"Cardiol. Clin."},{"issue":"11","key":"10.1016\/j.bcp.2019.04.003_b0130","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/14656566.2016.1197202","article-title":"Expert opinion: the therapeutic challenges faced by statin intolerance","volume":"17","author":"Patel","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14740338.2017.1238898","article-title":"Statin intolerance - a question of definition","volume":"16","author":"Algharably","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.003_b0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2019.04.003_b0145","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jcph.866","article-title":"Alternative treatment regimens with the PCSK9 inhibitors alirocumab and evolocumab: a pharmacokinetic and pharmacodynamic modeling approach","volume":"57","author":"Scherer","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.bcp.2019.04.003_b0150","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bcp.2019.04.003_b0155","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.003_b0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase subtilisin\/kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.003_b0170","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","article-title":"Application of PCSK9 inhibitors in practice","volume":"124","author":"Kaufman","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.04.003_b0180","doi-asserted-by":"crossref","DOI":"10.1007\/s40266-018-00632-x","article-title":"Drug therapy of dyslipidemia in the elderly","author":"Yandrapalli","year":"2019","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.bcp.2019.04.003_b0185","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the national lipid association","volume":"11","author":"Orringer","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"14","key":"10.1016\/j.bcp.2019.04.003_b0190","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 update of ESC\/EAS task force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.bcp.2019.04.003_b0195","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0205","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","article-title":"Development of novel DNA-encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics","volume":"27","author":"Khoshnejad","year":"2019","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"33","key":"10.1016\/j.bcp.2019.04.003_b0210","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jmb.2004.10.050","article-title":"Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity","volume":"345","author":"Henrich","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.003_b0225","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0230","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.chembiol.2013.11.014","article-title":"Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro","volume":"21","author":"Schroeder","year":"2014","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0235","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.003_b0240","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/jacs.7b09360","article-title":"Small molecule inhibitors of the PCSK9.LDLR interaction","volume":"140","author":"Taechalertpaisarn","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.003_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001882","article-title":"Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain","volume":"15","author":"Lintner","year":"2017","journal-title":"PLoS Biol."},{"issue":"11","key":"10.1016\/j.bcp.2019.04.003_b0250","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.chembiol.2016.08.016","article-title":"A small-molecule anti-secretagogue of PCSK9 targets the 80S ribosome to inhibit PCSK9 protein translation","volume":"23","author":"Petersen","year":"2016","journal-title":"Cell. Chem. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2019.04.003_b0255","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1021\/acs.jmedchem.8b00650","article-title":"Small molecule proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: hit to lead optimization of systemic agents","volume":"61","author":"Londregan","year":"2018","journal-title":"J. Med. Chem."},{"issue":"43","key":"10.1016\/j.bcp.2019.04.003_b0260","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.003_b0265","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","article-title":"A therapeutic peptide vaccine against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.003_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.bcp.2019.04.003_b0275","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:08:38Z","timestamp":1757768918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":55,"alternative-id":["S0006295219301285"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.003","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Keep recycling going: New approaches to reduce LDL-C","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}